Beximco Pharmagdr Regs Stock Profit Margin

R2WA Stock  EUR 0.41  0.00  0.00%   
BEXIMCO PHARMAGDR REGS fundamentals help investors to digest information that contributes to BEXIMCO PHARMAGDR's financial success or failures. It also enables traders to predict the movement of BEXIMCO Stock. The fundamental analysis module provides a way to measure BEXIMCO PHARMAGDR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BEXIMCO PHARMAGDR stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BEXIMCO PHARMAGDR REGS Company Profit Margin Analysis

BEXIMCO PHARMAGDR's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Profit Margin

 = 

Net Income

Revenue

X

100

More About Profit Margin | All Equity Analysis

Current BEXIMCO PHARMAGDR Profit Margin

    
  0.14 %  
Most of BEXIMCO PHARMAGDR's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BEXIMCO PHARMAGDR REGS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition

Based on the latest financial disclosure, BEXIMCO PHARMAGDR REGS has a Profit Margin of 0.1419%. This is 101.27% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The profit margin for all Germany stocks is 111.17% lower than that of the firm.

BEXIMCO Profit Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BEXIMCO PHARMAGDR's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BEXIMCO PHARMAGDR could also be used in its relative valuation, which is a method of valuing BEXIMCO PHARMAGDR by comparing valuation metrics of similar companies.
BEXIMCO PHARMAGDR is rated fifth in profit margin category among its peers.

BEXIMCO Fundamentals

About BEXIMCO PHARMAGDR Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BEXIMCO PHARMAGDR REGS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BEXIMCO PHARMAGDR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BEXIMCO PHARMAGDR REGS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in BEXIMCO Stock

BEXIMCO PHARMAGDR financial ratios help investors to determine whether BEXIMCO Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BEXIMCO with respect to the benefits of owning BEXIMCO PHARMAGDR security.